Squarepoint Ops LLC Sells 37,088 Shares of ANI Pharmaceuticals, Inc. $ANIP

Key Points

• Squarepoint Ops LLC cut its ANI Pharmaceuticals stake by 58.4%, selling 37,088 shares and retaining 26,450 shares worth approximately $2.19 million. Institutional investors collectively own 76.05% of the company.
• ANI Pharmaceuticals exceeded quarterly expectations, reporting $2.21 in earnings per share versus the $2.04 consensus estimate, while revenue rose 25.8% year over year to $266.04 million.
• ANIP shares opened at $70.40, near their 12-month low, while analysts maintained a “Moderate Buy” consensus with an average price target of $105.57; insiders have sold 22,925 shares worth about $1.79 million over the past 90 days.

Squarepoint Ops LLC decreased its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 58.4% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 26,450 shares of the specialty pharmaceutical company's stock after selling 37,088 shares during the period. Squarepoint Ops LLC owned 0.12% of ANI Pharmaceuticals worth $2,190,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in ANIP. California State Teachers Retirement System grew its holdings in ANI Pharmaceuticals by 7,977.4% during the 2nd quarter. California State Teachers Retirement System now owns 1,983,574 shares of the specialty pharmaceutical company's stock valued at $164,200,000 after buying an additional 1,959,017 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of ANI Pharmaceuticals by 19.3% in the first quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company's stock worth $43,399,000 after buying an additional 91,153 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of ANI Pharmaceuticals by 8.9% in the first quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company's stock valued at $40,843,000 after acquiring an additional 43,523 shares during the period. Ranger Investment Management L.P. bought a new position in shares of ANI Pharmaceuticals in the second quarter valued at approximately $28,406,000. Finally, Deutsche Bank AG purchased a new position in ANI Pharmaceuticals during the second quarter valued at approximately $26,775,000. Institutional investors own 76.05% of the company's stock.

ANI Pharmaceuticals Stock Up 0.3%

Shares of NASDAQ ANIP opened at $70.40 on Tuesday. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. The business has a 50-day moving average of $76.97 and a 200-day moving average of $78.17. The firm has a market capitalization of $1.62 billion, a price-to-earnings ratio of 15.17 and a beta of 0.45. ANI Pharmaceuticals, Inc. has a 12 month low of $69.58 and a 12 month high of $99.39.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating analysts' consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The business had revenue of $266.04 million for the quarter, compared to the consensus estimate of $260.13 million. During the same period last year, the firm posted $1.80 earnings per share. ANI Pharmaceuticals's quarterly revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Sell-side analysts expect that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current fiscal year.

Insider Transactions at ANI Pharmaceuticals

In related news, Director Jeanne Thoma sold 1,000 shares of the company's stock in a transaction on Friday, September 11th. The shares were sold at an average price of $71.53, for a total value of $71,530.00. Following the completion of the transaction, the director directly owned 26,762 shares in the company, valued at approximately $1,914,285.86. The trade was a 3.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 3,162 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $77.00, for a total value of $243,474.00. Following the completion of the transaction, the senior vice president directly owned 75,534 shares in the company, valued at approximately $5,816,118. This represents a 4.02% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 22,925 shares of company stock worth $1,794,295. Company insiders own 8.10% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ANIP. Weiss Ratings lowered shares of ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a report on Tuesday, August 11th. Leerink Partners started coverage on shares of ANI Pharmaceuticals in a report on Wednesday, September 9th. They issued an "outperform" rating and a $104.00 price target for the company. Canaccord Genuity Group reduced their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating for the company in a research report on Monday, August 10th. Wall Street Zen cut shares of ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 8th. Finally, Guggenheim lowered their price objective on ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating on the stock in a research report on Monday, August 10th. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $105.57.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.

ANI's portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.